Zobrazeno 1 - 10 of 131 pro vyhledávání: '"Sakellariou-Thompson D"'
1
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
2
Akademický článek
Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma.
Autor: Amaria R; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Knisely A; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Vining D; Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Kopetz S; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Overman MJ; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Javle M; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Antonoff MB; Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Tzeng CD; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Wolff RA; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Pant S; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Lito K; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Rangel K; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Fellman B; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Yuan Y; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Lu KH; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Sakellariou-Thompson D; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Haymaker CL; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Forget MA; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Hwu P; Moffitt Cancer Center, Tampa, Florida, USA., Bernatchez C; SVP Discovery & Platforms, Therapeutics Discovery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Jazaeri AA; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA AAJazaeri@mdanderson.org.
Publikováno v: Journal for immunotherapy of cancer [J Immunother Cancer] 2024 Feb 02; Vol. 12 (2). Date of Electronic Publication: 2024 Feb 02.
Zobrazit plný text záznamu
3
Akademický článek
Single-Cell Sequencing Reveals Trajectory of Tumor-Infiltrating Lymphocyte States in Pancreatic Cancer.
Autor: Schalck A; Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas.; The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, Texas., Sakellariou-Thompson D; Department of Biologics Development, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Forget MA; Department of Biologics Development, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Sei E; Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Hughes TG; Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Reuben A; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Bai S; Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Hu M; Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Kumar T; Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas.; The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, Texas., Hurd MW; Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, Texas., Katz MHG; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Tzeng CD; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Pant S; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Javle M; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Fogelman DR; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Maitra A; The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, Texas.; Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Haymaker CL; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Kim MP; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Navin NE; Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas.; The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, Texas.; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Bernatchez C; Department of Biologics Development, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Publikováno v: Cancer discovery [Cancer Discov] 2022 Oct 05; Vol. 12 (10), pp. 2330-2349.
Zobrazit plný text záznamu
4
Akademický článek
CRISPR-mediated TGFBR2 knockout renders human ovarian cancer tumor-infiltrating lymphocytes resistant to TGF-β signaling.
Autor: Fix SM; Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Forget MA; Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Sakellariou-Thompson D; Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Wang Y; Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Griffiths TM; Biologics Development, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Lee M; Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Haymaker CL; Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Dominguez AL; Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Basar R; Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Reyes C; Cell Biology R&D, Thermo Fisher Scientific, Carlsbad, California, USA., Kumar S; Cell Biology R&D, Thermo Fisher Scientific, Carlsbad, California, USA., Meyer LA; Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Hwu P; Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA Patrick.Hwu@moffitt.org., Bernatchez C; Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Jazaeri AA; Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Publikováno v: Journal for immunotherapy of cancer [J Immunother Cancer] 2022 Jul; Vol. 10 (7).
Zobrazit plný text záznamu
5
Akademický článek
Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes.
Autor: Shah P; Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Forget MA; Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Biologics Development, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Frank ML; Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Jiang P; Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Sakellariou-Thompson D; Biologics Development, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Federico L; Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Khairullah R; Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Neutzler CA; Biologics Development, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Wistuba I; Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Chow CB; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Long Y; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Fujimoto J; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Lin SY; Department of Systems Biology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Maitra A; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Negrao MV; Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Mitchell KG; Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Weissferdt A; Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Vaporciyan AA; Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Cascone T; Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Roth JA; Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Zhang J; Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Sepesi B; Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Gibbons DL; Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Heymach JV; Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Haymaker CL; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., McGrail DJ; Department of Systems Biology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA cbernatchez@mdanderson.org AReuben@mdanderson.org djmcgrail@mdanderson.org., Reuben A; Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA cbernatchez@mdanderson.org AReuben@mdanderson.org djmcgrail@mdanderson.org., Bernatchez C; Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA cbernatchez@mdanderson.org AReuben@mdanderson.org djmcgrail@mdanderson.org.; Biologics Development, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Publikováno v: Journal for immunotherapy of cancer [J Immunother Cancer] 2022 Feb; Vol. 10 (2).
Zobrazit plný text záznamu
6
Akademický článek
METTL2B m3C RNA transferase: oncogenic role in ovarian cancer progression via regulation of the mTOR/AKT pathway and its link to the tumor immune microenvironment.
Autor: Meng, Yizi1 (AUTHOR), Meng, Yimei2 (AUTHOR), Zheng, Hui1 (AUTHOR), Huo, Jinru2 (AUTHOR), Li, Peiling2 (AUTHOR) peiley@hrbmu.edu.cn, Shan, Yanhong1 (AUTHOR) end6361@jlu.edu.cn, He, Jin1 (AUTHOR) hejin@jlu.edu.cn
Publikováno v: BMC Cancer. 11/27/2024, Vol. 24 Issue 1, p1-18. 18p.
Zobrazit plný text záznamu
7
Akademický článek
Spatiotemporal evolutionary process of osteosarcoma immune microenvironment remodeling and C1QBP‐driven drug resistance deciphered through single‐cell multi‐dimensional analysis.
Autor: Wu, Xin1 (AUTHOR), Tang, Ning2 (AUTHOR), Zhao, Qiangqiang3,4 (AUTHOR) zgxyws@163.com, Xiong, Jianbin5 (AUTHOR) profjbxiong@163.com
Publikováno v: Bioengineering & Translational Medicine. Sep2024, Vol. 9 Issue 5, p1-21. 21p.
Zobrazit plný text záznamu
8
Akademický článek
Potential clinical application of tumor-infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to chemotherapy.
Autor: Sakellariou-Thompson D; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (UT MDACC), Unit 904, 7455 Fannin, Houston, TX, 77054, USA., Forget MA; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (UT MDACC), Unit 904, 7455 Fannin, Houston, TX, 77054, USA., Hinchcliff E; Department of Gynecologic Oncology and Reproductive Medicine, UTMDACC, Houston, TX, USA., Celestino J; Department of Gynecologic Oncology and Reproductive Medicine, UTMDACC, Houston, TX, USA., Hwu P; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (UT MDACC), Unit 904, 7455 Fannin, Houston, TX, 77054, USA., Jazaeri AA; Department of Gynecologic Oncology and Reproductive Medicine, UTMDACC, Houston, TX, USA., Haymaker C; Department of Translational Molecular Pathology, UT MDACC, Unit 2951, 2130 W. Holcombe Blvd., Houston, TX, 77030, USA. chaymaker@mdanderson.org., Bernatchez C; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (UT MDACC), Unit 904, 7455 Fannin, Houston, TX, 77054, USA. cbernatchez@mdanderson.org.; Department of Translational Molecular Pathology, UT MDACC, Unit 2951, 2130 W. Holcombe Blvd., Houston, TX, 77030, USA. cbernatchez@mdanderson.org.
Publikováno v: Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2019 Nov; Vol. 68 (11), pp. 1747-1757. Date of Electronic Publication: 2019 Oct 10.
Zobrazit plný text záznamu
9
Akademický článek
Utilizing T-cell Activation Signals 1, 2, and 3 for Tumor-infiltrating Lymphocytes (TIL) Expansion: The Advantage Over the Sole Use of Interleukin-2 in Cutaneous and Uveal Melanoma.
Autor: Tavera RJ; Departments of Melanoma Medical Oncology., Forget MA; Departments of Melanoma Medical Oncology., Kim YU; Departments of Melanoma Medical Oncology., Sakellariou-Thompson D; Departments of Melanoma Medical Oncology., Creasy CA; Departments of Melanoma Medical Oncology., Bhatta A; Departments of Melanoma Medical Oncology., Fulbright OJ; Departments of Melanoma Medical Oncology., Ramachandran R; Departments of Melanoma Medical Oncology., Thorsen ST; Departments of Melanoma Medical Oncology., Flores E; Departments of Melanoma Medical Oncology., Wahl A; Departments of Melanoma Medical Oncology., Gonzalez AM; Departments of Melanoma Medical Oncology., Toth C; Departments of Melanoma Medical Oncology., Wardell S; Departments of Melanoma Medical Oncology., Mansaray R; Departments of Melanoma Medical Oncology., Radvanyi LG; Departments of Melanoma Medical Oncology., Gombos DS; Head and Neck Surgery, The University of Texas MD Anderson Cancer Center (MDACC), Houston, TX., Patel SP; Departments of Melanoma Medical Oncology., Hwu P; Departments of Melanoma Medical Oncology., Amaria RN; Departments of Melanoma Medical Oncology., Bernatchez C; Departments of Melanoma Medical Oncology., Haymaker C; Departments of Melanoma Medical Oncology.
Publikováno v: Journal of immunotherapy (Hagerstown, Md. : 1997) [J Immunother] 2018 Nov/Dec; Vol. 41 (9), pp. 399-405.
Zobrazit plný text záznamu
10
Akademický článek
Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome.
Autor: Forget MA; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas., Haymaker C; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas., Hess KR; Department of Biostatistics, The University of Texas MDACC, Houston, Texas., Meng YJ; Broad Institute of Harvard and MIT, Cambridge, Massachusetts.; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Creasy C; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas., Karpinets T; Department of Genomic Medicine, The University of Texas MDACC, Houston, Texas., Fulbright OJ; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas., Roszik J; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas.; Department of Genomic Medicine, The University of Texas MDACC, Houston, Texas., Woodman SE; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas., Kim YU; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas., Sakellariou-Thompson D; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas., Bhatta A; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas., Wahl A; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas., Flores E; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas., Thorsen ST; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas., Tavera RJ; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas., Ramachandran R; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas., Gonzalez AM; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas., Toth CL; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas., Wardell S; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas., Mansaray R; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas., Patel V; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas., Carpio DJ; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas., Vaughn C; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas., Farinas CM; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas., Velasquez PG; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas., Hwu WJ; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas., Patel SP; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas., Davies MA; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas., Diab A; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas., Glitza IC; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas., Tawbi H; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas., Wong MK; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas., Cain S; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas., Ross MI; Department of Surgical Oncology, The University of Texas MDACC, Houston, Texas., Lee JE; Department of Surgical Oncology, The University of Texas MDACC, Houston, Texas., Gershenwald JE; Department of Surgical Oncology, The University of Texas MDACC, Houston, Texas., Lucci A; Department of Surgical Oncology, The University of Texas MDACC, Houston, Texas., Royal R; Department of Surgical Oncology, The University of Texas MDACC, Houston, Texas., Cormier JN; Department of Surgical Oncology, The University of Texas MDACC, Houston, Texas., Wargo JA; Department of Genomic Medicine, The University of Texas MDACC, Houston, Texas.; Department of Surgical Oncology, The University of Texas MDACC, Houston, Texas., Radvanyi LG; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas., Torres-Cabala CA; Department of Pathology, The University of Texas MDACC, Houston, Texas., Beroukhim R; Broad Institute of Harvard and MIT, Cambridge, Massachusetts.; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Hwu P; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas., Amaria RN; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas. cbernatchez@mdanderson.org rnamaria@mdanderson.org., Bernatchez C; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas. cbernatchez@mdanderson.org rnamaria@mdanderson.org.
Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2018 Sep 15; Vol. 24 (18), pp. 4416-4428. Date of Electronic Publication: 2018 May 30.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje